[Chemotherapy of small cell bronchial cancer with a combination of carboplatin, vincristine and etoposide].
In a phase II study, the combination of the new platinum derivative carboplatin with vincristine and etoposide is associated with a remission rate of 81.8 per cent (LD 84.4%, ED 79.1%). The median survival rates for patients with limited disease have not yet been reached, and, at 11.5 months in the case of patients with extensive disease, are unexpectedly high. In comparison with combinations containing cisplatin, the present combination would appear to be superior, and its toxicity is also lower. For a definitive assessment of its usefulness, it must be compared with other standard treatment regimens in prospective, randomized studies.
Gatzemeier
U
U
Pneumologisch-Onkologische Abteilung, Krankenhaus Grosshansdorf.
Achterrath
W
W
Heckmayr
M
M
Hossfeld
D K
DK
Neuhauss
R
R
Reck
M
M
Zschaber
R
R
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D009944:Organoplatinum Compounds; D014750:Vincristine; D005047:Etoposide; D016190:Carboplatin
Die Chemotherapie des kleinzelligen Bronchialkarzinoms mit einer Kombination aus Carboplatin, Vincristin und Etoposid.